Serological Markers: Are they Reliable for the Diagnosis of Low Bone Mass Density?
| ℹ | The corresponding author of this article was changed, and a Corrigendum regarding this change was published in Vol. 20 No. 2 (2021). |
Authors
- Abdelghnay H. Abdelghany Faculty of Medicine, University of Alexandria, Alexandria, Egypt
-
Osama A. Shaikhomar
Physiology Department, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia
- Eslam A. Header Clinical Nutrition Department, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Saudi Arabia
- Hassan M. Bukhari Clinical Nutrition Department, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Saudi Arabia
- Naeem F. Qusty Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Saudi Arabia
DOI:
https://doi.org/10.3923/pjn.2020.430.437Keywords:
Alkaline phosphatase, bone mass density, bone turn over, calcium, osteocalcin, osteoporosis, vitamin DAbstract
Background and Objective: Bone remodeling includes balanced bone formation and resorption and low bone mass density (BMD) occurs when there is a higher rate of resorption. Osteoporosis is a chronic asymptomatic disease with bone fragility that increases an impending risk of bone fracture caused by minor trauma. Calcium and vitamin D are critical for bone mineralization and health. Bone-specific alkaline phosphatase (ALP) and osteocalcin (OC) are markers of bone formation. This study was conducted to test the utility of serological parameters as reliable markers in the diagnosis of low BMD compared with BMD measurements. Materials and Methods: In this study 715 Saudi students of Umm Al-Qura University aged 19-22 years were assessed for serum levels of calcium, vitamin D, ALP and OC. The BMD was measured by dual-energy X-ray absorptiometry (DEXA) and the results were statistically analyzed. Results: We found that 26.57% of the studied cases had low BMD and showed significantly higher levels of serum calcium, bone-specific ALP and OC with significantly lower serum levels of vitamin D compared to control cases. There was no correlation between serum markers and BMD measurements in cases of low BMD. Conclusion: Serum markers may be useful for screening and predicting people who are at risk of developing BMD as well as for assessing responses to osteoporosis therapy. Low BMD is better diagnosed by a combination of serum markers and measurements of BMD.
References
Gkiatas, I., M. Lykissas, I. Kostas-Agnantis, A. Korompilias, A. Batistatou and A. Beris, 2015. Factors affecting bone growth. Am. J. Orthopedics, 44: 61-67.
Haglin, J.M., S. Jain, A.E.M. Eltorai and A.H. Daniels, 2017. Bone Growth Stimulation: A Critical Analysis Review. JBJS Rev.
Chen, X., Z. Wang, N. Duan, G. Zhu, E.M. Schwarz and C. Xie, 2018. Osteoblast-osteoclast interactions. Connective Tissue Res., 59: 99-107.
Fang, A. and K. Li, 2014. Calcium deficiency: where does the diagnostic criterion come from and by what is bone health influenced? Chin. Med. J., 127: 4161-4163.
Kovacs, C.S., 2015. Calcium, phosphorus, and bone metabolism in the fetus and newborn. Early Hum. Dev., 91: 623-628.
Spustová, V. and R. Dzúrik, 2004. Vitamin D: synthesis, metabolism, regulation, and an assessment of its deficiency in patients with chronic renal disease. VnitÅ™nà lékaÅ™stvÃ, 50: 537-543.
Reid, I.R. 2017. Vitamin D effect on bone mineral density and fractures. Endocrinol. Metab. Clinics North Am., 46: 935-945.
Paschalis, E.P., S. Gamsjaeger, N. Hassler, A. Fahrleitner-Pammer and H. Dobnig et al., 2016. Vitamin D and calcium supplementation for three years in postmenopausal osteoporosis significantly alters bone mineral and organic matrix quality. Bone, 95: 41-46.
Bolland, M.J., A. Grey and I.R. Reid, 2015. Should we prescribe calcium or vitamin D supplements to treat or prevent osteoporosis? Climacteric, 18: 22-31.
Gozashti, M.H., A. Shahesmaeili and N.A. Zadeh, 2011. Is opium addiction a risk factor for bone loss? Iran. Red Crescent Med. J., 13: 464-468.
Main, R.P., 2017. Osteocytes and the bone lacunar-canalicular system: Insights into bone biology and skeletal function using bone tissue microstructure. Int. J. Paleopathol., 18: 44-46.
Li, Q., J. Wu, W. Xi, X. Chen, W. Wang et al., 2019. Ctrp4, a new adipokine, promotes the differentiation of osteoblasts. Biochem. Biophys. Res. Commun., 512: 224-229.
Oury, J. and F. Oury, 2018. Osteocalcin, a key molecule for bone endocrine functions. Med. Sci., 34: 54-62.
Grote-Koska, D., R. Klauke, K. Brand and G. Schumann, 2016. Alkaline phosphatase activity – pH impact on the measurement result. Clin. Chem. Lab. Med., Vol. 55, No. 7.
Bailey, S., G. Karsenty, C. Gundberg and D. Vashishth, 2017. Osteocalcin and osteopontin influence bone morphology and mechanical properties. Ann. New York Acad. Sci., 1409: 79-84.
Moser, S.C. and B.C.J. van der Eerden, 2019. Osteocalcin—A versatile bone-derived hormone. Front. Endocrinol., Vol. 9.
Oladipo, O.O., A.J. DeCrescenzo, C.P. Marquez and A.O. Okorodudu, 2017. Increased alkaline phosphatase in a child. Clin. Chem., 63: 1174-1175.
Van Dort, M.J., E.A.P.M. Romme, F.W.J.M. Smeenk, P.P.P.M. Geusens, E.F.M. Wouters and J.P. van den Bergh, 2018. Diagnosis of vertebral deformities on chest CT and DXA compared to routine lateral thoracic spine X-ray. Osteoporosis Int., 29: 1285-1293.
Clark, E.P. and J.B. Collip, 1925. A study of the Tisdall method for the determination of blood serum calcium with a suggested modification. J. Biol. Chem., 63: 461-464.
Bayard, F., P. Bee and J.P. Louvet, 2008. Measurement of plasma 25-hydroxycholecalciferol in man. Eur. J. Clin. Invest., 2: 195-198.
Behr, W. and J. Barnert, 2020. Quantification of bone alkaline phosphatase in serum by precipitation with wheat-germ lectin: a simplified method and its clinical plausibility. Clin. Chem., 32: 1960-1966.
Wenz, I., R. Reissmann and H. Börnig, 1991. Determination of osteocalcin in serum by an ultramicro-ELISA with alkaline phosphatase as marker enzyme. Biomed. Biochim. Acta, 50: 145-149.
Hannemann, A., N. Friedrich, C. Spielhagen, R. Rettig, T. Ittermann, M. Nauck and H. Wallaschofski 2013. Reference intervals for serum osteocalcin concentrations in adult men and women from the study of health in Pomerania. BMC Endocr. Disord.
Kung, A.W., T. Fan, L. Xu, W.B. Xia and I.H. Park et al., 2013. Factors influencing diagnosis and treatment of osteoporosis after a fragility fracture among postmenopausal women in Asian countries: a retrospective study. BMC Women's Health.
Cortet, B., E. Biver, S. Borg, F. Chopin and E. Hoppé et al., 2011. Management of male osteoporosis: lessons for clinical practice. Joint Bone Spine, 78: S208-S210.
Hlaing, T.T. and J.E. Compston, 2014. Biochemical markers of bone turnover – uses and limitations. Ann. Clin. Biochem., 51: 189-202.
Yedavally-Yellayi, S., A.M. Ho and E.M. Patalinghug, 2018. Update on osteoporosis. Primary Care: Clinics in Office Pract., 46: 175-190.
Eastell, R. and P. Szulc, 2017. Use of bone turnover markers in postmenopausal osteoporosis. Lancet Diabetes Endocrinol., 5: 908-923.
Kuo, T.R. and C.H. Chen, 2017. Bone biomarker for the clinical assessment of osteoporosis: recent developments and future perspectives. Biomarker Res.
Siddiqui, J.A. and N.C. Partridge, 2016. Physiological bone remodeling: Systemic regulation and growth factor involvement. Physiology, 31: 233-245.
Armas, L.A.G. and R.R. Recker, 2012. Pathophysiology of osteoporosis: New mechanistic insights. Endocrinol. Metab. Clinics North Am., 41: 475-486.
Cano, A., P. Chedraui, D.G. Goulis, P. Lopes and G. Mishra et al., 2018. Calcium in the prevention of postmenopausal osteoporosis: EMAS clinical guide. Maturitas, 107: 7-12.
Chiodini, I. and M.J. Bolland, 2018. Calcium supplementation in osteoporosis: useful or harmful? Eur. J. Endocrinol., 178: D13-D25.
Weng, X.M. and J.P. Pan, 2013. Bone alkaline phosphatase and N-MID osteocalcin in monitoring of osteoporosis treatment with recombinant human parathyroid hormone 1-34. Zhejiang Da Xue Xue Bao Yi Xue Ban, 42: 578-582.
Diemar, S.S., L.T. Møllehave, N. Quardon, L. Lylloff, B.H. Thuesen, A. Linneberg and N.R. Jørgensen, 2020. Effects of age and sex on osteocalcin and bone-specific alkaline phosphatase—reference intervals and confounders for two bone formation markers. Arch. Osteoporosis.
Al-Daghri, N.M., S.H. Abd-Alrahman, A. Panigrahy, Y. Al-Saleh and Naji Aljohani et al., 2017. Efficacy of Vitamin D interventional strategies in Saudi children and adults. J. Steroid Biochem. Mol. Biol., 180: 29-34.
Garriguet, D., 2011. Bone health: osteoporosis, calcium and vitamin D. Health Rep., 22: 7-14.
Shetty, S., N. Kapoor, J.D. Bondu, N. Thomas and T.V. Paul, 2016. Bone turnover markers: Emerging tool in the management of osteoporosis. Indian J. Endocrinol. Metab., 20: 846-852.
Kalaiselvi V.S., K. Prabhu, M. Ramesh and V. Venkatesan, 2013. The association of serum osteocalcin with the bone mineral density in post menopausal women. J. Clin. Diagn. Res., 7: 814-816.
Mukaiyama, K., M. Kamimura, S. Uchiyama, S. Ikegami, Y. Nakamura and H. Kato, 2015. Elevation of serum alkaline phosphatase (ALP) level in postmenopausal women is caused by high bone turnover. Aging Clin. Exp. Res., 27: 413-418.
Nakamura, Y., T. Suzuki and H. Kato, 2017. Serum bone alkaline phosphatase is a useful marker to evaluate lumbar bone mineral density in Japanese postmenopausal osteoporotic women during denosumab treatment. Ther. Clin. Risk Manage., 13: 1343-1348.
Tariq, S., S. Tariq, K.P. Lone and S. Khaliq, 2019. Alkaline phosphatase is a predictor of Bone Mineral Density in postmenopausal females. Pak. J. Med. Sci., 35: 749-753.
Alonso, N., B. Larrazâ€Prieto, K. Berg, Z. Lambert and P. Redmond et al., 2019. Lossâ€ofâ€function mutations in the ALPL gene presenting with adult onset osteoporosis and low serum concentrations of total alkaline phosphatase. J. Bone Miner. Res., 35: 657-661.
Hicks, R.W., L. Umnitz and D.C. Seibert, 2018. Hypophosphatasia: A rare disorder. J. Am. Assoc. Nurse Pract., 30: 600-602.
Tsiantouli, E., A. Trombetti and S. Ferrari, 2017. Hypophosphatasia. Rev. Med. Suisse., 13: 855-858.
Ray, C.S., B. Singh, I. Jena, S. Behera and S. Ray, 2017. Low alkaline phosphatase (ALP) In adult population an indicator of zinc (Zn) and magnesium (Mg) deficiency. Curr. Res. Nutr. Food Sci., 5: 347-352.
Arise, R.O., F.F. Davies and S.O. Malomo, 2008. Independent and interactive effects of Mg2+ and Co2+ on some kinetic parameters of rat kidney alkaline phosphatase. Sci. Res. Essay, 3: 488-494.
Lumachi, F., M. Ermani, V. Camozzi, V. Tombolan and G. Luisetto, 2009. Changes of bone formation markers osteocalcin and bone-specific alkaline phosphatase in postmenopausal women with osteoporosis. Ann. N. Y. Acad. Sci., 1173: E60-E63.
Zhou, X.W., X.Y. Wu, L. Luo, L.J. Guo and M.X. Lei et al., 2011. The relationship between bone turnover markers and BMD decreasing rates in Chinese middle-aged women. Clin. Chim. Acta, 412: 1648-1657.
Liu, Z., R. Chen, Y. Jiang, Y. Yang and L. He et al., 2019. A meta-analysis of serum osteocalcin level in postmenopausal osteoporotic women compared to controls. BMC Musculoskelet Disord.
Bauer, D.C., 2019. Clinical use of bone turnover markers. JAMA, 322: 569-570.
Jain, S. and P. Camacho, 2018. Use of bone turnover markers in the management of osteoporosis. Curr. Opin. Endocrinol. Diabetes Obesity, 25: 366-372.
Downloads
Published
Issue
Section
License
Copyright (c) 2020 The Author(s)
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
